Harrow Health price target raised to $34.40 from $33.70 at Ladenburg

Ladenburg analyst Jeffrey Cohen raised the firm’s price target on Harrow Health to $34.40 from $33.70 and keeps a Buy rating on the shares post the Q2 report. In addition to revenue growth from existing product segments, the company also began recognizing revenue from newly acquired products, the analyst tells investors in a research note.